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MEDPRAT Overview
• Medical Extensible Dynamic Probabilistic Risk Assessment Tool 
• Goal: Provide a medical risk prediction tool that is extensible to the majority of 
exploration missions.  
The tool will ideally utilize the available space and terrestrial medical data and human health 
research to assess space flight medical risk in a manner consistent with other risk measures used in 
spacecraft and mission design.  Also, the tool is tailorable, accommodating new data, new findings, 
new medical capabilities, new missions and new outcomes.   
• Human health research is the process that improves our understanding of 
medical conditions, medical equipment, space and terrestrial standards and 
practices.
• This tool provides risk based medical system design information necessary to 
evaluate new technologies, procedures, research insights and mission plans.
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Set Selector Theory
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• Resource space is massively multi-dimensional (225-D), 
increasing extrapolation error with larger steps
• The benefit/cost function is not linear but is monotonic
• Need a robust method that supports future data
• Solve like a gradient descent algorithm
• Don’t know the differential, but move in the direction 
away from poorest resources, likely the steepest gradient
• MEDPRAT-SEL removes the poorest resources and tries 
again; the user chooses the step size
Gradient Descent
• Resource-Condition-Health feedback loop
• Blue components and paths are new for MEDPRAT-SEL
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MEDPRAT-SEL Architecture
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• Kinds of Resources
– Rate-limited – (momentary only), benefit accrued immediately
– Quantity-limited – updated over mission time as resources exhausted
• ΔIFI – relative incremental functional impairment
– Functional impairment due a crew’s condition
• Benefit metrics – ΔQTL (from ΔIFI), ΔRTDC, ΔLOCL
– at the level of treatment for resource availability relative to no resources 
– at that moment in simulated mission time, so all feature interactions are honored
• Condition Evaluation
– At the end of a trial, metrics accumulated with clinical phases of occurrences of conditions are accumulated for 
conditions ×cases (best v. worst case)
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Datapaths in Simulator
• Resource Evaluation
– Then, conditions ×cases benefit metrics redistributed to resources
– By number of “essential” treatments for condition
– By number of available resources
– For alternates, by available resources and by equivalence
• Divide resource amounts into parcels
– User provides a parcel size for each resource; the set selector’s resolution of in selecting amounts of 
that resource
– Each resource amount divided into a number of whole parcels, and a fraction of a last parcel
– Record the number of whole parcels,  benefit / parcel of the whole parcels and the benefit of the last 
parcel
• For the series of trials
– Accumulate by whole parcels, benefit / parcel of whole parcels, benefit of last parcel
– Scale for the number of trials and record to file
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More Datapaths in Simulator
• Accumulate groups of numbers of parcels
– Groups, so data storage size is less dependent of parcel size
– Cumulative benefit from large to small number of parcels
– Cost lookup
• Choose best parcels
– Calculate benefit from linear combination of ΔQTL, ΔRTDC, ΔLOCL
– Calculate cost from linear combination of mass, volume
– Order groups by benefit / cost
– Discard poorest
• Set selector control logic
– Iterate until limits met
– Branch for bulky parcels
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Datapaths in Optimizer
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Stepping and Branching
• MEDPRAT-SEL runs simulator and medical resource 
selector together, iteratively, making incremental
changes to resource set
• MEDPRAT-SEL ordinarily makes small steps but a 
single large item will force a large step
• To avoid errors from this, MEDPRAT-SEL provides a 
branching option, evaluating sets without and with 
large items
• The user can access all information about all 
candidate sets and make a final decision whether 
to include or exclude a large, low value item at 
post-processing
Cost
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Large jump (red) results from removal of large, low value item 
Re-run with large, low value item excluded
Good
Bad
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Q 
Components
• Simulator – runs simulated missions
• Uses limited medical resource set
• Collects resource benefit statistics ( QTL,  RTDC,  LOCL)
• Optimizer – ranks resource instances by benefit / cost
• Uses resource benefit statistics
• Generates reduced medical resource quantities
• Set Selector – runs simulator and optimizer
• Controls limits of simulation-optimization sequences
• Manages combinations of bulky resources
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Set Selector 
Simulator Optimizer 
Parameters
• Number of trials per simulator run
• Cost: coefficients for mass, volume in linear combination
• Benefit: coefficients for RTDC, LOCL, QTL in linear combination
• Control
• Benefit-cost factor for reduction of set size by optimization
• Cost factor (of item relative to set), threshold for larger, bulky items handled by combination
• Limits on repetition of optimization sequence
• Set size reduced to a given cost and/or benefit
• Number of iterations
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Development Methodologies
• Agile
– daily meetings on Slack, in touch with clients
• Object-Oriented Design
• Open-source languages
– C++, Python; cheaper deployment
• Documentation, 100+ pp.
– User’s Manual, Software Design Doc., Testing Doc.
• Regression tests
– With every run of simulator
• Solutions built upon existing code
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Hazard of Extrapolating Simulator Results
• We saw cases where a fully-untreated, permanently impaired crew was 
impaired less by a minor condition than if treated
• Estimating Functional Impairment using only fully-untreated and fully-treated 
data can give distorted results. FI is non-linear.
Functional Impairment Fully 
Untreated
Fully 
Treated
Untreated –
Treated
Pre-Existing (FI1) 50% 0 50% 
New Condition Alone (FI2) 33% 25% 8%
Total (FI3 = FI1 + FI2 – FI1FI2) 67% 25% 42%
New Condition Attributed
(FI3 – FI1 if FI1 > FI2; FI2 if FI1 < FI2)
17% 25% –8%
Impairment inputs
Standard calculations
Unreasonable result
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Graph of Hazard of Extrapolating Results
• FI attributed to 
condition 2 reduces 
as FI1 increases, and 
reduces abruptly 
when FI1 becomes 
larger than FI2
• In the extreme, less 
FI is attributed to 
condition 2 when 
untreated rather 
than treated
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Interaction of Features in the Model
Feature Name Impact Interaction Invariants
Treatment Occurrence, 
QTL
Resource to 
condition
One crew
Anti-overdose Resource Condition to 
condition
One resource, 
one crew
Scarcity of resources Condition Crew to crew One resource
Cumulative FI QTL Occurrence to 
occurrence
One crew
One occurrence of condition at 
a time
Incidence rate Occurrence to 
occurrence
One crew
RTDC, LOCL Resources, QTL Occurrence to 
conditions
One crew
Alternate Treatment Resources Resource to 
resource
One condition, 
one crew
Susceptibility Incidence rate Condition to 
condition
One crew
Contagion Incidence rate Crew to crew One condition
• The interactions and non-linearities 
in the model make larger 
extrapolations less accurate 
• Benefit of a resource depends on the 
presence of other resources in the 
set
• May lead to errors in selecting 
medical resources 
• Some features have limited 
representation in fully-treated or 
fully-untreated paradigms
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• Each resource (rectangle) has a 
benefit (height) and cost (width)
• A set with the best (benefit/cost) 
for a given cost or benefit does 
not necessarily consist of the 
best (benefit/cost) resources
• The best resources come within 
one resource of a best set for a 
given cost or benefit target, and 
if that resource is fungible, the 
set is best
• Benefit of a resource depends on 
the presence of other resources 
in the set
• Uncertainty precludes optimality
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Optimization Example
Good
Bad
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Extrapolation across Resource Space
• MEDPRAT runs simulator and 
medical resource selector together, 
iteratively, making incremental
changes to resource set
• Resource space is massively multi-
dimensional, increasing 
extrapolation error
• The benefit/cost function is not 
linear but is monotonic
• Need a robust method that supports 
future data
• MEDPRAT-SEL removes the worst 
resources and tries again; the user 
chooses the step size
MEDPRAT
Not MEDPRAT
Good
Bad
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Usage Notes (Gotchas)
• Execution time is very sensitive to cost factor
– After increasing cost factor, use quick simulator runs (1k trials) to see how long it takes. 
But quick simulator runs are noisy and introduce some additional execution time
• In resource source file, use constraints on quantities of resources
– Set selector will not produce a set outside of the given limits
– Initial_Quantity field ‒ maximum quantity in set. Use NaN to leave unconstrained
– Keep_Quantity field ‒ minimum quantity in set. Use 0 to leave unconstrained
• In resource source file, use parcel size to control resolution of MEDPRAT-SEL
• Optimizer makes decisions based on estimated benefit
– Set selector results are taken directly from the simulator
– After running the set selector, every set is available to be simulated again to get more 
detailed results
• More research / experimentation, better data needed
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• Get good input database and set selector program parameters
– Software results are no better than the inputs
• Low-hanging fruit
– Dismiss uncompetitive resources; lock-in large, high-value resources early
– Use shorter simulator runs early
• When approaching targets, let the tool work
– Reduce cost factor to try more combinations of items 
– Lengthen simulator runs to get accurate results for rare events
• Run very competitive sets through simulator again
– Get detailed reports, do sensitivity analyses, etc.
• Once you have a good set, don’t believe it
– Ask what-if questions, make small modifications and rerun simulator
– Find problems with the model and help build a better one
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How to Use MEDPRAT-SEL
Actual Results – Summary File
Set 
ID
Cost Benefit
Absolute 
Benefit
Mass Volume RTDC LOCL QTL
Parent 
Set ID
Branch 
Set ID
Base 
Set ID
Resource 
ID
Initial 
Quantity
0 0 0 -73.7402 0 0 0.423 0.003 73.7402 0 0 0 NaN NaN
1 NaN 58.5885 -15.1517 NaN NaN 0.027 0.001 15.1517 1 1 1 NaN NaN
2 39.33884 NaN NaN 39.33884 66369.36 NaN NaN NaN 1 1 1 NaN NaN
3 39.33884 NaN NaN 39.33884 66369.36 NaN NaN NaN 2 2 1 221 1
4 39.33884 NaN NaN 39.33884 66369.36 NaN NaN NaN 3 3 1 119 1
5 39.33884 58.2674 -15.4728 39.33884 66369.36 0.042 0.001 15.4728 4 4 1 115 1
6 34.98373 58.843 -14.8972 34.98373 42446.96 0.029 0.001 14.8972 5 4 1 115 1
7 31.30079 58.6368 -15.1034 31.30079 34710.7 0.038 0.003 15.1034 6 4 1 115 1
8 28.41846 57.3654 -16.3748 28.41846 31973.94 0.047 0 16.3748 7 4 1 115 1
9 26.32716 55.0675 -18.6727 26.32716 26316.96 0.079 0 18.6727 8 4 1 115 1
10 25.01703 51.1981 -22.5421 25.01703 22838.72 0.13 0.003 22.5421 9 4 1 115 1
11 24.34167 44.7334 -29.0068 24.34167 18174.58 0.173 0.003 29.0068 10 4 1 115 1
12 23.97167 41.6486 -32.0916 23.97167 17965 0.195 0.007 32.0916 11 4 1 115 1
13 23.75735 38.064 -35.6762 23.75735 17804.91 0.217 0.004 35.6762 12 4 1 115 1
14 23.68036 36.0943 -37.6459 23.68036 17722.76 0.257 0.005 37.6459 13 4 1 115 1
15 NaN 58.8413 -14.8989 NaN NaN 0.032 0 14.8989 4 4 15 115 0
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Preferred to minimize QTL 
rather than LOCL
1. Eyewash waste water bag (2)
2. Space station eye wash
3. Eye wash goggles & tubing
4. Blood pressure cuff – large
5. Panoptic ophthalmoscope
6. SAM splint - leg/arm splint
7. Smooth forceps
8. Scissors – trauma
9. Skin staple remover
10. Afrin (Oxymetazoline) 0.05% 15mL 
bottle (3)
Preferred to minimize LOCL 
rather than QTL
1. IV fluid 1L (1000 mL) (2)
2. Ambu bag and mask
3. Intraosseous injection device
4. Suction device
5. Variable oxygen system
6. ILMA endotracheal tube 7.0/7.5 & endotracheal tube 
7.0/8.0
7. Albuterol inhaler (Proventil) 90 mcg, 6.7 gm (2)
8. Dexamethasone (Decadron) 10 mg injectable (5)
9. Suction device syringe
10. Adrenaline (epinephrine 1:10000) 10mL 
MEDPRAT-SEL Preliminary Results
• Top ten resources by total mass; 5 kg medical resource set
• Lunar DRM: 6 crew, 14 days, 8 EVA
• 10,000 trials per run; 10% mass decrease per run
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Demo Trade Study
• Pilot of a pilot trade study
• Based on planned trade study by pilot project
• Based on 42 day Gateway mission including RTDC and PEC
• A bulky resource X was selected as candidate for 
miniaturization research:
‒ How much would productive time increase if resource X could be 
miniaturized to 10% mass for Gateway mission?
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Results
• Each point represents 1M mission simulations
• Each line represents optimization by removing high cost, low 
benefit resource instances
• Different lines represent different combinations of high cost 
resource quantities
• Horizontal axis is mass in kg of entire set
• Vertical axis is Quality Time Lost (QTL) in days relative to 
untreated (empty set). Benefit of treatment is upward.
• Upper left is good; lower right is bad.
• Pair of charts: control case, experiment case.
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• How does productive time increase if 
resource X could be miniaturized to 10% 
mass?
• What resources are taken in sets of 
comparable mass?
– Experimental set only (1 ea): resource X, 
Fluorescein 1 mg strips
– Control set only (1 ea): suction device, dental elevator -
301 (i), dental elevator - 34s (j), foam electrodes, Lopressor 
(Metoprolol) 50 mg, Adrenaline (Epinephrine 1:10000) 10 ml, 
Valium (Diazepam) 5 mg/ml, 2 ml syringe, Lotrimin AF cream 
(Clotrimazole) 1%, 30 gm tube, dental adhesive (76 gms), 
Promethazine injectable (Phenergan) 50 mg/ml single dose vial, 
Vicodin HP (hydrocodone/ acetaminophen HP) 10 mg/660 mg, 
ILMA cue card, Mupirocin (Bactroban) 2%, 22 gm tube, Phenergan 
(Promethazine tablet) 25 mg, Motrin (Ibuprofen) 400mg, Dulcolax
(Bisacodyl) tablet 5mg, refresh artificial tears 
(Carboxymethylcellulose) 0.5%, 0.4ml bottle, Fluocinonide 0.05%, 
30gm tube, Tylenol (Acetaminophen) 325 mg, Sudafed 12 hour 
(Pseudoephedrine) 120 mg, Imodium (Loperamide HCL) 2 mg 
tablet, Prednisone 20 mg, Moxifloxacin (Avelox) 0.5%, 3ml bottle
Control
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